For many patients diagnosed with non-small cell lung cancer (NSCLC) whose tumors lack specific genetic mutations, immunotherapy has become a crucial first-line treatment. However, the initial promise of these therapies often fades as cancer cells develop resistance, halting their effectiveness. Understanding the complex mechanisms behind this resistance – and ultimately overcoming it – is now a central focus of cancer research, with recent studies highlighting the critical role of tumor heterogeneity and the demand for more personalized treatment approaches.
The challenge isn’t simply that cancer evolves. it’s *how* it evolves. NSCLC isn’t a uniform disease. Even within a single patient, tumors can exhibit significant variations, both before and during immunotherapy treatment. Researchers using advanced techniques like multiplexed imaging mass cytometry have observed that different subtypes of tumor cells respond differently to immunotherapy, and that the development of resistance is often linked to changes in T-cell infiltration. In other words that a treatment effective against one part of a tumor might be ineffective against another, a problem compounded by the tumor’s ability to adapt over time. Further complicating matters, resistance isn’t solely driven by changes within the tumor itself. Factors within the tumor microenvironment – the surrounding cells, blood vessels, and immune components – also play a significant role, allowing cancer cells to evade the immune system and continue growing.
The Heterogeneity Hurdle in Clinical Trials
A major obstacle in developing strategies to overcome immunotherapy resistance is the way clinical trials are currently designed. Traditionally, trials haven’t fully accounted for the profound heterogeneity of both the tumor and its surrounding microenvironment. Preclinical models, while valuable, often fail to replicate the full complexity of these factors, creating a disconnect between promising laboratory results and clinical outcomes. This makes it incredibly tricky to predict which therapeutic combinations will be effective against the diverse resistance mechanisms that can emerge in individual patients.
Recent results from the phase III LATIFY study, presented at the European Lung Cancer Congress 2026, underscore this challenge. The study investigated the combination of ceralasertib – a drug that inhibits the ataxia-telangiectasia-related (ATR) DNA damage response kinase – with durvalumab, an immunotherapy drug. According to data presented (LBA1), the combination did not demonstrate a statistically significant improvement in overall survival compared to standard chemotherapy (docetaxel) in 594 patients with advanced NSCLC who had progressed after prior treatment. Objective response rates were 7.7% for the combination therapy and 17.3% for docetaxel. This outcome wasn’t entirely unexpected, given earlier phase II results from the HUDSON study, which showed an objective response rate of 13.9% (Nat Med. 2024;30:716–729).
Hopeful Signals from Gotistobart
Despite the setback with ceralasertib, other research offers a glimmer of hope. Preliminary findings from the phase III PRESERVE-003 study, also presented in Copenhagen, showed more encouraging results with gotistobart, an anti-CTLA-4 monoclonal antibody. The study, involving 87 patients with squamous NSCLC who had progressed after prior immunotherapy and chemotherapy, reported an objective response rate of 20.0% with gotistobart, compared to just 4.8% with docetaxel (Abstract 3O). Importantly, the median overall survival had not yet been reached in the gotistobart arm at the time of the analysis, compared to 9.95 months in the docetaxel arm after a median follow-up of approximately 14.5 months. PRESERVE-003 is ongoing, and further data are anticipated.
The Need for Personalized Approaches
Both the LATIFY and PRESERVE-003 studies highlight the difficulty of developing broadly effective strategies to overcome acquired resistance to immunotherapy. The current lack of tailored treatment options for this patient population underscores the urgent need for a more nuanced understanding of resistance mechanisms. Researchers are increasingly focused on leveraging technological advancements that allow for rapid and detailed analysis of tumors and their microenvironments. This includes techniques that can identify specific biomarkers – measurable indicators of a biological state – that predict how a patient will respond to a particular therapy.
While previous phase III trials combining multi-tyrosine kinase inhibitors (TKIs) with immunotherapy have largely failed to demonstrate a significant overall survival benefit, some phase II studies, such as SAKK 17/18 (Ann Oncol. 2023;34(Suppl. 2):S807–S808) and RECLAIM (J Thoracic Oncol. 2025;20(Suppl. 1):S610), have shown promising objective response rates. Antibody-drug conjugate (ADC) strategies are also emerging as potential novel avenues for treatment, but, as of now, reliable biomarkers to guide treatment decisions in this complex landscape remain elusive.
The future of NSCLC treatment likely lies in a more personalized approach, guided by a deeper understanding of the molecular evolution of resistance. This will require re-analyzing tumors at the time of resistance to immunotherapy, creating opportunities to identify specific vulnerabilities and tailor treatment strategies accordingly. Advances in technologies that can rapidly analyze tumors and their microenvironment are crucial to unlocking this potential and ultimately improving outcomes for patients with this challenging disease.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Further results from the PRESERVE-003 study are expected to provide additional insights into the potential of gotistobart in treating NSCLC that has become resistant to immunotherapy. Researchers will continue to explore novel strategies and biomarkers to personalize treatment and improve outcomes for patients facing this difficult diagnosis. Share your thoughts and experiences in the comments below.
